Table 1.
Dravet Syndrome patients treated with Belviq® (lorcaserin) show reduced seizure frequency
| Patient | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Age (years) | 10 | 18 | 10 | 7 | 14 |
| Weight (kg) | 28 | 46 | 23 | 24 | 35 |
| Dose (mg/kg/day) | 0.25 | 0.27 | 0.19 | 0.32 | 0.31 |
| Prior treatments | CLZ CZP KD LMT LVT PRM OXC RUF TPX VPA | CBZ CBD CLZ CLB CZP FBM LMT LVT PRM PHB TPM VPA CC KD VNS | ESM FBM LMT LVT MSM VPA VMP ZNM KD | CZP ESM LVT LZP STP TPM ZNM KD | CBZ FBM GBP LCM LMT LVT OXC PHB PRED RUF STP VNS VPM ZNM KD |
| Concurrent AEDs | CLB STP VPA | CZP STP ZNM | KD TPM VPA | BRO CBD CLB VPA | CLB TPX VPA |
| Prior seizure frequency | FS: 50/day | MS: numerous daily | MS: daily | AS: 12/h | MS: constant throughout the day |
| GTC clusters: 1/ month | FS + GTC: 10/ month (requires rescue medications) | GTC seizures: 100/month (clusters 7–10) | FS: 3–5 / week | GTC seizures: 1–2/ week | |
| NCS: 1/ month | |||||
| Seizure frequency after treatment: first 3 months | Seizure free initial 3 weeks, cluster of seizures then again seizure free for 2 weeks | Seizure free for 2weeks | GTC seizures: 46/ month (GTC clusters of 1–3 seizures) | 1–2 seizure free days/ week | MS: initially reduced in the morning then increases to constant throughout the late afternoon |
| Cluster of seizures once a month with (FS, GTC) | MS: occasional | MS: daily | AS or FS: 3/ month | GTC: 1–2/ week | |
| FS + GTC: 1/month (no rescue medications) | GTC: 1–2 /day | ||||
| NCS: 1/ month | |||||
| Seizure frequency after treatment: following first 3 months | Gradual increase in seizures with return to baseline frequency | MS: clusters 1–2/ week | Seizures gradually decreased to 16/ month with some seizure free nights then seizures increased to baseline | Gradual increase in seizures, seizure free days stopped 9 months after treatment | Unchanged, Belviq® tapered off with no change in seizure frequency |
| FS + GTC: 1–2/ month and (no rescue medica tions required) | No increase in seizure when medication stopped | ||||
| Duration treat ment (months) | 12 months, still taking | 12 months, still taking | 14 months | 13 months | 9 months |
| Restarted due to increased seizures treated for 2 months, stopped to participate in other drug study | |||||
| Side effects | none | none | Vomiting and decreased appetite | Decreased appetite | Decreased appetite |
AS = atonic seizures; BRO = bromides; CBD = cannabidiol; CBZ = carbamazepine; CLB = clobazam; CZP = clonazepam; CLZ = clorazepate; CC = corpus callosotomy; ESM = ethosuximide; FBM = felbamate; FS = focal seizures; GBP = gabapentin; GTC = generalized tonic clonic seizures; KD = ketongenic diet; LCM = lacosamide; LMT = lamotrigine; LVT = levitiracetam; LZP = lorazepam; MS = myoclonic seizures; MSM = methosuximide; NCS = non-convulsive status; OXC = oxcarbazipine; PHB = phenobarbital; PRM = primodone; PRED = predinisone; RFM = rufinamide; STP = stiripentol; TPM = topiramate; VPA = valproic acid; VNS = vagus nerve stimulator; VPM = verapamil; ZNM = zonisamide.